Review Article
Recent Advances and the Mechanism of Astaxanthin in Ophthalmological Diseases
Table 1
Summary of in clinical studies on eye and AST.
| Study type | Number | AST dose and duration | Referred ocular disease | Biological effects | Index | References |
| Prospective, | 60 patients/120 eyes | 12 mg/day | DES | Improve the symptoms and signs | Osd, tbut, FBUT, CFS, MG | [42] | One-group | 30 ± 2 days | RCT | 43 | 20 mg/kg/day | DES | Improve tear production and tear film stability | Schirmer test, TBUT | [14] | 8 weeks | Reduce levels of ROS | RCT | 20 | 12 mg/day | ARMD | Choroidal blood flow velocity | — | [44] | 4 weeks | RCT | 27 | 4 mg/day | ARMD | — | mfERG | [43] | 12 months | RCT | 145 | 4 mg/day | ARMD | Stable/improve contrast sensitivity and visual acuity | — | [45] | 12 months | RCT | 35 | 6 mg/day 2 weeks | ARMD | Affect O2.- scavenging activity in the aqueous humor | — | [1, 49] |
|
|